Does severe anemia caused by dose-dense paclitaxel-carboplatin combination therapy have an effect on the survival of patients with epithelial ovarian cancer? Retrospective analysis of the Japanese gynecologic oncology group 3016 trial

International Journal of Gynecological Cancer

Volumn 21, Issue 9, 2011, Pages 1585-1591

  Kumagai, Seisuke ^a   Sugiyama, Toru ^a   Shoji, Tadahiro ^a   Michimae, Hirofumi ^b   Katsumata, Noriyuki ^c   Aoki, Daisuke ^d   Terauchi, Fumitoshi ^e   Jobo, Toshiko ^f   Ochiai, Kazunori ^g   Yasuda, Makoto ^g  

^a IWATE MEDICAL UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d KEIO UNIVERSITY   (Japan)

^e TOKYO MEDICAL UNIVERSITY   (Japan)

^f Social Insurance Sagamino Hospital   (Japan)

^g JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anemia; Chemotherapy; Hemoglobin; Ovarian cancer; Survival

Indexed keywords

CARBOPLATIN; HEMOGLOBIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DISEASE SEVERITY; EPITHELIAL OVARIAN CANCER; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; OVARIAN EPITHELIAL CANCER; OVARY TUMOR; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HEMOGLOBINS; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; RETROSPECTIVE STUDIES;

EID: 84857397039     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e318229266a     Document Type: Article

References (20)

1. Barrett-Lee P, Bokemeyer C, Gascón P, et al. Management of cancer-related anemia in patients with breast or gynecologic cancer: new insights based on results from the European Cancer Anemia Survey. Oncologist. 2005;10:743-757. (Pubitemid 41567288)
2. Barrett-Lee PJ, Bailey NP, O'Brien MER, et al. Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer. 2000;82:93-97. (Pubitemid 30008965)
3. Caro JJ, Salas M, Ward A, et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer. 2001;91: 2214-2221. (Pubitemid 32552805)
4. Grogan M, Thomas GM, Meland I, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer. 1999;86:1528-1536. (Pubitemid 29489787)
5. Winter III WE, Maxwell GL, Tian C, et al. Association of hemoglobin level with survival in cervical carcinoma patients treated with concurrent cisplatin and radiotherapy: a Gynecologic Oncology Group Study. Gynecol Oncol. 2004;94:495-501. (Pubitemid 39024559)
6. Thomas G, Ali S, Hoebers FJP, et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol. 2008;108: 317-325.
7. Blohmer JU, Wurschmidt F, Petry U, et al. Results with sequential adjuvant chemo-radiotherapy with vs without epoetin alfa for patients with high-risk cervical cancer: results of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study. Ann Oncol. 2004;15:477.
8. Munstedt K, Kovacic M, Zygmunt M, et al. Impact of hemoglobin levels before and during chemotherapy on survival of patients with ovarian cancer. Int J Oncol. 2003;23:837-843.
9. Eichbaum MH, Weiss LM, Bruckner T, et al. Prognostic impact of hemoglobin levels before and during carboplatin/taxane-based chemotherapy in patients with primary invasive epithelial ovarian cancer. Med Sci Monit. 2009;15:CR156-CR163.
10. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374: 1331-1338.
11. National Cancer Institute. Cancer Therapy Evaluation Program: Common Toxicity Criteria, Version 2.0. Bethesda, MD: DCTD, NCI. NIH, DHHS; 1998.
12. Rosenbaum PR., Rubin DR. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
13. D'Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265-2281.
14. Henke M, Laszig R, Rübe C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:1255-1260. (Pubitemid 37324251)
15. Overgaard J, Hoff C, Hansen HS, et al. Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC) - the Danish Head and Neck Cancer Group DAHANCA 10 randomized trial. Eur J Cancer. 2007;5:7.
16. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005;23:5960-5972.
17. Aapro M, Leonard RC, Barnadas A, et al. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline-and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J Clin Oncol. 2008;26:592-598. (Pubitemid 351264353)
18. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009;373:1532-1542.
19. Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer. 2010;102:301-315.
20. Delarue R, Haioun C, Broussais-Guillaumot F, et al. Efficacy and safety of prophylactic use of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: Results of the interim analysis of the LNH03-6B GELA study. 51st annual meeting of the American Society of Hematology, abstract 1701, 2009.